Biolimus-Eluting StenT For de-novo coRonary artery dIsease in patiENts with Diabetes mellituS: the BESTFRIENDS multicentre registry

Emanuele Meliga, Alessandro Lupi, Azeem Latib, Andrea Gagnor, Giacomo Boccuzzi, Marco Alcantara, Primiano Lombardi, Alessandro Sticchi, Tiziana C. Aranzulla, Innocenzo Scrocca, Ferdinando Varbella, Mauro de Benedictis, Antonio Colombo, Maria Rosa Conte

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

AIMS: Coronary inflammation and healing influence outcomes of diabetic patients treated with Percutaneous coronary revascularization (PCI). Stents covered with biodegradable polymers (bp) may offer advantages over nonerodible polymer ones, because polymer reabsorption extinguish coronary inflammation and favours healing. Aim of our study was to assess the safety and efficacy of bp-biolimus-eluting stent (bp-BES) in a large series of consecutive diabetic patients. METHODS: From 2009 to 2013 we retrospectively enrolled consecutive diabetic patients treated with PCI and bp-BES implantation. Primary end points were target lesion revascularization (TLR) and stent thrombosis rates. RESULTS: Study cohort counted 747 patients. Multivessel disease was present in 48.2% with a mean stent/patient ratio of 1.860.78. During the hospital stay no stent thrombosis occurred. At 3-year follow-up we observed a 1.5% cumulative incidence of cardiac death, 1.1% of myocardial infarction and 6.3% of TLR. Stent thrombosis occurred in 1.1% of patients, all in the first 2?years of follow-up. Kaplan–Meier analysis showed a TLR-free survival at 1 and 3?years of 97.2 and 96.1%, respectively. CONCLUSION: PCI with bp-BES seems to be well tolerated and effective in a large unselected population of diabetic patients. The good results observed were maintained at 3?years of follow-up.

Original languageEnglish
JournalJournal of Cardiovascular Medicine
DOIs
Publication statusAccepted/In press - Nov 21 2015

Fingerprint

Stents
Registries
Coronary Artery Disease
Diabetes Mellitus
Polymers
Percutaneous Coronary Intervention
Thrombosis
Inflammation
Length of Stay
Cohort Studies
Myocardial Infarction
Safety
Survival
Incidence
Population

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Biolimus-Eluting StenT For de-novo coRonary artery dIsease in patiENts with Diabetes mellituS : the BESTFRIENDS multicentre registry. / Meliga, Emanuele; Lupi, Alessandro; Latib, Azeem; Gagnor, Andrea; Boccuzzi, Giacomo; Alcantara, Marco; Lombardi, Primiano; Sticchi, Alessandro; Aranzulla, Tiziana C.; Scrocca, Innocenzo; Varbella, Ferdinando; de Benedictis, Mauro; Colombo, Antonio; Conte, Maria Rosa.

In: Journal of Cardiovascular Medicine, 21.11.2015.

Research output: Contribution to journalArticle

Meliga, E, Lupi, A, Latib, A, Gagnor, A, Boccuzzi, G, Alcantara, M, Lombardi, P, Sticchi, A, Aranzulla, TC, Scrocca, I, Varbella, F, de Benedictis, M, Colombo, A & Conte, MR 2015, 'Biolimus-Eluting StenT For de-novo coRonary artery dIsease in patiENts with Diabetes mellituS: the BESTFRIENDS multicentre registry', Journal of Cardiovascular Medicine. https://doi.org/10.2459/JCM.0000000000000335
Meliga, Emanuele ; Lupi, Alessandro ; Latib, Azeem ; Gagnor, Andrea ; Boccuzzi, Giacomo ; Alcantara, Marco ; Lombardi, Primiano ; Sticchi, Alessandro ; Aranzulla, Tiziana C. ; Scrocca, Innocenzo ; Varbella, Ferdinando ; de Benedictis, Mauro ; Colombo, Antonio ; Conte, Maria Rosa. / Biolimus-Eluting StenT For de-novo coRonary artery dIsease in patiENts with Diabetes mellituS : the BESTFRIENDS multicentre registry. In: Journal of Cardiovascular Medicine. 2015.
@article{e063926dbc9d4e3f8d493aea55339cc4,
title = "Biolimus-Eluting StenT For de-novo coRonary artery dIsease in patiENts with Diabetes mellituS: the BESTFRIENDS multicentre registry",
abstract = "AIMS: Coronary inflammation and healing influence outcomes of diabetic patients treated with Percutaneous coronary revascularization (PCI). Stents covered with biodegradable polymers (bp) may offer advantages over nonerodible polymer ones, because polymer reabsorption extinguish coronary inflammation and favours healing. Aim of our study was to assess the safety and efficacy of bp-biolimus-eluting stent (bp-BES) in a large series of consecutive diabetic patients. METHODS: From 2009 to 2013 we retrospectively enrolled consecutive diabetic patients treated with PCI and bp-BES implantation. Primary end points were target lesion revascularization (TLR) and stent thrombosis rates. RESULTS: Study cohort counted 747 patients. Multivessel disease was present in 48.2{\%} with a mean stent/patient ratio of 1.860.78. During the hospital stay no stent thrombosis occurred. At 3-year follow-up we observed a 1.5{\%} cumulative incidence of cardiac death, 1.1{\%} of myocardial infarction and 6.3{\%} of TLR. Stent thrombosis occurred in 1.1{\%} of patients, all in the first 2?years of follow-up. Kaplan–Meier analysis showed a TLR-free survival at 1 and 3?years of 97.2 and 96.1{\%}, respectively. CONCLUSION: PCI with bp-BES seems to be well tolerated and effective in a large unselected population of diabetic patients. The good results observed were maintained at 3?years of follow-up.",
author = "Emanuele Meliga and Alessandro Lupi and Azeem Latib and Andrea Gagnor and Giacomo Boccuzzi and Marco Alcantara and Primiano Lombardi and Alessandro Sticchi and Aranzulla, {Tiziana C.} and Innocenzo Scrocca and Ferdinando Varbella and {de Benedictis}, Mauro and Antonio Colombo and Conte, {Maria Rosa}",
year = "2015",
month = "11",
day = "21",
doi = "10.2459/JCM.0000000000000335",
language = "English",
journal = "Journal of Cardiovascular Medicine",
issn = "1558-2027",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Biolimus-Eluting StenT For de-novo coRonary artery dIsease in patiENts with Diabetes mellituS

T2 - the BESTFRIENDS multicentre registry

AU - Meliga, Emanuele

AU - Lupi, Alessandro

AU - Latib, Azeem

AU - Gagnor, Andrea

AU - Boccuzzi, Giacomo

AU - Alcantara, Marco

AU - Lombardi, Primiano

AU - Sticchi, Alessandro

AU - Aranzulla, Tiziana C.

AU - Scrocca, Innocenzo

AU - Varbella, Ferdinando

AU - de Benedictis, Mauro

AU - Colombo, Antonio

AU - Conte, Maria Rosa

PY - 2015/11/21

Y1 - 2015/11/21

N2 - AIMS: Coronary inflammation and healing influence outcomes of diabetic patients treated with Percutaneous coronary revascularization (PCI). Stents covered with biodegradable polymers (bp) may offer advantages over nonerodible polymer ones, because polymer reabsorption extinguish coronary inflammation and favours healing. Aim of our study was to assess the safety and efficacy of bp-biolimus-eluting stent (bp-BES) in a large series of consecutive diabetic patients. METHODS: From 2009 to 2013 we retrospectively enrolled consecutive diabetic patients treated with PCI and bp-BES implantation. Primary end points were target lesion revascularization (TLR) and stent thrombosis rates. RESULTS: Study cohort counted 747 patients. Multivessel disease was present in 48.2% with a mean stent/patient ratio of 1.860.78. During the hospital stay no stent thrombosis occurred. At 3-year follow-up we observed a 1.5% cumulative incidence of cardiac death, 1.1% of myocardial infarction and 6.3% of TLR. Stent thrombosis occurred in 1.1% of patients, all in the first 2?years of follow-up. Kaplan–Meier analysis showed a TLR-free survival at 1 and 3?years of 97.2 and 96.1%, respectively. CONCLUSION: PCI with bp-BES seems to be well tolerated and effective in a large unselected population of diabetic patients. The good results observed were maintained at 3?years of follow-up.

AB - AIMS: Coronary inflammation and healing influence outcomes of diabetic patients treated with Percutaneous coronary revascularization (PCI). Stents covered with biodegradable polymers (bp) may offer advantages over nonerodible polymer ones, because polymer reabsorption extinguish coronary inflammation and favours healing. Aim of our study was to assess the safety and efficacy of bp-biolimus-eluting stent (bp-BES) in a large series of consecutive diabetic patients. METHODS: From 2009 to 2013 we retrospectively enrolled consecutive diabetic patients treated with PCI and bp-BES implantation. Primary end points were target lesion revascularization (TLR) and stent thrombosis rates. RESULTS: Study cohort counted 747 patients. Multivessel disease was present in 48.2% with a mean stent/patient ratio of 1.860.78. During the hospital stay no stent thrombosis occurred. At 3-year follow-up we observed a 1.5% cumulative incidence of cardiac death, 1.1% of myocardial infarction and 6.3% of TLR. Stent thrombosis occurred in 1.1% of patients, all in the first 2?years of follow-up. Kaplan–Meier analysis showed a TLR-free survival at 1 and 3?years of 97.2 and 96.1%, respectively. CONCLUSION: PCI with bp-BES seems to be well tolerated and effective in a large unselected population of diabetic patients. The good results observed were maintained at 3?years of follow-up.

UR - http://www.scopus.com/inward/record.url?scp=84947969601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947969601&partnerID=8YFLogxK

U2 - 10.2459/JCM.0000000000000335

DO - 10.2459/JCM.0000000000000335

M3 - Article

AN - SCOPUS:84947969601

JO - Journal of Cardiovascular Medicine

JF - Journal of Cardiovascular Medicine

SN - 1558-2027

ER -